BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9607581)

  • 1. p53 and thymidylate synthase expression in untreated stage II colon cancer: associations with recurrence, survival, and site.
    Lenz HJ; Danenberg KD; Leichman CG; Florentine B; Johnston PG; Groshen S; Zhou L; Xiong YP; Danenberg PV; Leichman LP
    Clin Cancer Res; 1998 May; 4(5):1227-34. PubMed ID: 9607581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival.
    Edler D; Kressner U; Ragnhammar P; Johnston PG; Magnusson I; Glimelius B; Påhlman L; Lindmark G; Blomgren H
    Clin Cancer Res; 2000 Feb; 6(2):488-92. PubMed ID: 10690528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thymidylate synthase expression: an independent prognostic factor for local recurrence, distant metastasis, disease-free and overall survival in rectal cancer.
    Edler D; Hallström M; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
    Clin Cancer Res; 2000 Apr; 6(4):1378-84. PubMed ID: 10778966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival.
    Lenz HJ; Hayashi K; Salonga D; Danenberg KD; Danenberg PV; Metzger R; Banerjee D; Bertino JR; Groshen S; Leichman LP; Leichman CG
    Clin Cancer Res; 1998 May; 4(5):1243-50. PubMed ID: 9607583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell cycle proteins predict recurrence in stage II and III colon cancer.
    Belt EJ; Brosens RP; Delis-van Diemen PM; Bril H; Tijssen M; van Essen DF; Heymans MW; Beliën JA; Stockmann HB; Meijer S; Meijer GA
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S682-92. PubMed ID: 22311118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of p53 expression in advanced-stage ovarian serous borderline tumors.
    Gershenson DM; Deavers M; Diaz S; Tortolero-Luna G; Miller BE; Bast RC; Mills GB; Silva EG
    Clin Cancer Res; 1999 Dec; 5(12):4053-8. PubMed ID: 10632339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymidylate synthase expression correlates closely with E2F1 expression in colon cancer.
    Kasahara M; Takahashi Y; Nagata T; Asai S; Eguchi T; Ishii Y; Fujii M; Ishikawa K
    Clin Cancer Res; 2000 Jul; 6(7):2707-11. PubMed ID: 10914714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Kornmann M; Schwabe W; Sander S; Kron M; Sträter J; Polat S; Kettner E; Weiser HF; Baumann W; Schramm H; Häusler P; Ott K; Behnke D; Staib L; Beger HG; Link KH
    Clin Cancer Res; 2003 Sep; 9(11):4116-24. PubMed ID: 14519634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
    Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
    Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
    Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial.
    Sakamoto J; Hamashima H; Suzuki H; Ito K; Mai M; Saji S; Fukushima M; Matsushita Y; Nakazato H
    Oncol Rep; 2003; 10(5):1081-90. PubMed ID: 12883662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of KRAS and TP53 mutations on survival in patients with left- and right-sided Dukes' C colon cancer.
    Bleeker WA; Hayes VM; Karrenbeld A; Hofstra RM; Hermans J; Buys CC; Plukker JT
    Am J Gastroenterol; 2000 Oct; 95(10):2953-7. PubMed ID: 11051374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.
    Aschele C; Debernardis D; Tunesi G; Maley F; Sobrero A
    Clin Cancer Res; 2000 Dec; 6(12):4797-802. PubMed ID: 11156237
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas.
    Sinicrope FA; Hart J; Hsu HA; Lemoine M; Michelassi F; Stephens LC
    Clin Cancer Res; 1999 Jul; 5(7):1793-804. PubMed ID: 10430084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.
    Paradiso A; Simone G; Petroni S; Leone B; Vallejo C; Lacava J; Romero A; Machiavelli M; De Lena M; Allegra CJ; Johnston PG
    Br J Cancer; 2000 Feb; 82(3):560-7. PubMed ID: 10682666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer.
    Huang CL; Liu D; Nakano J; Yokomise H; Ueno M; Kadota K; Wada H
    Clin Cancer Res; 2007 Dec; 13(23):6938-46. PubMed ID: 18056168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of prophylactic hepatic arterial chemotherapy for liver metastases of Dukes C colorectal cancer--correlation with tumoral expression of dihydropyrimidine dehydrogenase, thymidylate synthase, p53, or orotate phosphoribosyl transferase].
    Ishida H; Yamada H; Shirakawa K; Nakada H; Ohsawa T; Takeuchi I; Okada N; Yokoyama M; Inokuma S; Suzuki T; Odaka A; Hoshino T; Murata N; Hashimoto D; Itoyama S; Mori T; Matsumoto Y; Miura T
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1621-6. PubMed ID: 14619479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer.
    Ichikawa W; Uetake H; Shirota Y; Yamada H; Nishi N; Nihei Z; Sugihara K; Hirayama R
    Clin Cancer Res; 2003 Feb; 9(2):786-91. PubMed ID: 12576451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.